The use of combination therapy in pulmonary arterial hypertension: new developments

N. Galie*, L. Negro* and G. Simonneau#

ABSTRACT: There is a strong clinical rationale for combination therapy in pulmonary arterial hypertension (PAH), as several pathological pathways have been implicated in its pathogenesis and no single agent has yet been shown to deliver completely satisfactory results. Registry data indicate that use of combination therapy is in fact common in existing clinical practice, even though support has been largely empirical or derived from small-scale observational studies. Data from large, adequately powered, randomised controlled trials of combination therapy in PAH are now emerging and suggest that combination therapy may be clinically beneficial. Studies of bosentan in combination with prostanoids and phosphodiesterase (PDE)-5 inhibitors show consistent evidence of improvements in exercise capacity compared with placebo. Similar improvements have been observed with PDE-5 inhibitors in combination with prostanoids. The appropriate timing of combination therapy requires further evaluation but goal-oriented therapy using combinations of oral and inhaled drugs has been shown to provide acceptable long-term results in patients with advanced PAH. Monitoring should be performed regularly and be based on repeatable, noninvasive, measurable parameters that have prognostic value.

KEYWORDS: Combination therapy, endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension
symptomatic improvements but later regress [7]. Combination therapy using drugs targeted at the different pathways implicated in pulmonary vascular dysfunction is a logical, increasingly used option in the management of PAH, albeit largely empirically based [6, 8]. In this review, we will discuss the rationale for using combination therapy in PAH, examine the growing body of evidence to support its clinical use, and consider which patients might benefit most.

**RATIONALE FOR COMBINATION THERAPY**

Although treatable, PAH is still an incurable disease. Given the malignant nature of PAH, there is a case for taking an aggressive approach towards treatment. Certainly, this approach has been successfully employed in the treatment of other serious diseases, such as congestive heart failure [9], HIV infection [10] and cancer [11], where use of combination therapy is routine. Moreover, with evidence to suggest that at least three separate pathways are involved in the pathogenesis of PAH, there is a sound rationale for the concomitant use of two or more drugs in the treatment of PAH. To date, no single agent has been shown to deliver completely satisfactory improvements in patients in World Health Organization (WHO) functional class III/IV who have a poor prognosis despite targeted monotherapy. Obviously any clinical benefit to be derived from combining two or more drugs has to be considered in light of the risk of drug—drug interactions and the possible increased risk of side-effects.

**CURRENT DATA ON COMBINATION THERAPY**

Drug therapy for PAH, which presently includes prostanooids, ERAs and PDE-5 inhibitors, is recommended in treatment guidelines for most patients with PAH [12–14]. However, these guidelines primarily focus on the use of monotherapy in patients with advanced disease (WHO functional class III/IV); combination therapy warranted little mention in early treatment algorithms where it was seen primarily as reserve therapy before recourse to lung transplantation. Now, however, as data from clinical trials designed to evaluate the efficacy and safety of combination therapy has become available, this approach may be revised.

**ERA plus prostanoids**

The BREATHE-2 trial (Bosentan Randomised Trial of Endothelin Antagonist Therapy for PAH) was the first randomised, double-blind, placebo-controlled study to explore the potential clinical benefits of simultaneously combining bosentan with epoprostenol in treatment of severe PAH (WHO functional class III/IV) [15]. Of the 33 patients enrolled, those in the combined treatment arm showed a trend, albeit not statistically significant, towards improvements in cardio-pulmonary haemodynamics compared with those on epoprostenol alone. The subsequent STEP study (Safety and Pilot Efficacy Trial in Combination with Bosentan for Evaluation in Pulmonary Arterial Hypertension) in 67 PAH patients (mostly WHO functional class III) showed that the addition of inhaled iloprost to stable bosentan monotherapy resulted in significant improvements in functional class, haemodynamics and time to clinical worsening when compared with placebo [16]. Change from baseline in 6-min walking distance (6MWD) also showed greater improvement in patients receiving combination therapy compared with placebo recipients (p=0.051). Combination therapy proved both efficacious and well tolerated; syncope was notably less frequent and severe in the combination treatment arm than that reported in the AIR (Aerosolised Iloprost Randomised) study, possibly because of background bosentan therapy.

The potential benefits of combining bosentan with the long-acting prostacyclin derivative treprostinil have been investigated in two recently published studies [17, 18]. In an open-label study in 12 patients with symptomatic PAH despite bosentan treatment, the addition of inhaled treprostinil led to significant improvements in 6MWD and functional class (nine out of 11 patients improved from WHO functional class III to II),

**FIGURE 1.** Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1 (Haemodynamic effects of a single dose of sildenafil in symptomatic patients on bosentan treatment for pulmonary arterial hypertension) study at baseline-2 (mean 889, 95% CI 656–1,121) and 60 min after sildenafil (mean 778, 95% CI 561–995) (per-protocol set). Mean per cent change -15%; 95% CI -21– -10; p<0.0001. Data taken from [20].

**FIGURE 2.** The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES clinical trial (Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil). ■: epoprostenol plus sildenafil; ●: epoprostenol plus placebo. *: placebo-adjusted increase of 28.8 m, 95% CI 13.9–43.8; p<0.001. Reproduced from [22] with permission of the publisher.
as well as haemodynamics and time to clinical worsening [17]. Significant improvements in exercise capacity from inhaled treprostinil as add-on therapy to bosentan (or sildenafil) have since been confirmed in the large, randomised, double-blind, placebo-controlled TRIUMPH I (Treprostinil Inhalation Used for the Management of Pulmonary Hypertension) study [18]. Of the 212 (90%) patients who completed 12 weeks of combination therapy, median 6MWD increased by 20 m compared with placebo (p<0.0006). This was consistent with other studies, and combination treatment was well tolerated.

**ERA plus PDE-5 inhibitors**
Both bosentan and PDE-5 inhibitors are administered orally, making concomitant administration simple and convenient. Evidence that bosentan in combination with sildenafil may benefit patients with mildly symptomatic disease (WHO

### TABLE 1
Summary of combination therapy studies in pulmonary arterial hypertension (PAH) involving small numbers of patients and case reports

| Combination by background therapy | Patients n | Study duration | Aetiology of PAH | Key findings: combination versus baseline therapy alone/placebo | Ref. |
|-----------------------------------|------------|----------------|------------------|---------------------------------------------------------------|-----|
| **Prostanoids**                   |            |                |                  |                                                               |     |
| Epoprostenol + iloprost           | 8          | Single dose    | IPAH             | Significant improvements in mean \(P_{pa}\), CI, \(S_VO_2\), and \(P_{aO_2}\) | [23]|
| Beraprost + iloprost              | 23         | 12 months     | PAH-CHD          | Improvement in 6MWD and RVSP                                 | [24]|
| Beraprost/iloprost + bosentan     | 20         | 16 months     | IPAH             | Improvement in 6MWD                                          | [25]|
| Epoprostenol + bosentan           | 16         | 13.5 months   | IPAH, thromboembolic | Significant improvement in 6MWD and Tei index               | [26]|
|                                  | 8          | 1 yr          | IPAH             | Reduction in epoprostenol dose and side-effects              | [27]|
|                                  |            |                |                  | Discontinuation of epoprostenol and stabilisation of haemodynamics for \(<1\) yr in three patients |     |
|                                  | 8          | 1 yr          | IPAH             | Significant decrease in mean \(P_{pa}\)                      | [28]|
|                                  |            |                |                  | Delay in disease progression                                 |     |
| Iloprost + bosentan               | 9          | 12 weeks      | Not given        | Significant improvement in exercise capacity                | [29]|
| Treprostinal + bosentan           | 19         | ~3 yrs        | Not given        | Significant additional improvement in \(P_{pa}\), 6MWD and Borg dyspnoea scale | [30]|
| Epoprostenol + sildenafil         | 5          | 3 months      | IPAH             | Improvement in mean \(P_{pa}\) and WHO functional class     | [31]|
|                                  | 3          | 5 months      | IPAH, PAH-CHD    | Reduced mean \(P_{pa}\) and PVR                              | [32]|
|                                  | 3          | 2 h           | IPAH             | Increased 6MWD                                              | [33]|
|                                  | 30         | 3 h           | IPAH, CTEPH      | Increased vasodilation                                       | [34]|
|                                  | 14         | 9–12 months   | PAH unresponsive to iloprost | Improved 6MWD, haemodynamics and WHO functional class | [35]|
| Prostanoids + sildenafil          | 20         | 2 yrs         | Not given        | Significant improvement in WHO functional class and signs of right heart failure | [36]|
|                                  | 4          | Not given     | IPAH, PAH-CTD    | Increase in 6MWD after 1- and 2-yr follow-up                | [37]|
| Bosentan + sildenafil             | 9          | 12 months     | IPAH             | Improvements in 6MWD and CPET                               | [38]|
|                                  | 3          | \(<24\) months | IPAH             | Improvement in functional capacity, BNP                      | [39]|
|                                  | 11         | 1.1 yrs       | IPAH, PAH-CTD    | Improvement in WHO functional class, 6MWD and mean \(P_{pa}\) | [40]|
|                                  | 25         | 3 months      | IPAH, PAH-SSc    | Improved WHO functional class and 6MWD in IPAH but not in PAH-SSc | [41]|
|                                  | 10         | 6 months      | IPAH, PAH-CTD    | Increase in 6MWD                                            | [42]|
| Bosentan + prostanoids            | 35         | 3 months      | IPAH             | Improvements in 6MWD, CI, mean \(P_{pa}\) and WHO functional class | [43]|
| Bosentan + iloprost              | 40         | 12 weeks      | IPAH             | No effect on 6MWD                                           | [44]|
|                                  | 67         | 12 weeks      | IPAH, APAH       | Significant increase in 6MWD and WHO functional class       | [16]|
| Sildenafil + beraprost            | 1          | 1 month       | PAH-SSc          | Decrease in \(P_{pa}\) and PVR                              | [45]|

**Notes:**
- IPAH: idiopathic PAH; \(P_{pa}\): pulmonary arterial pressure; CI: cardiac index; \(S_VO_2\): mixed venous oxygen saturation; \(P_{aO_2}\): arterial oxygen tension; CHD: congenital heart disease; 6MWD: 6-min walk distance; RVSP: right ventricular systolic pressure; \(P_{ra}\): right arterial pressure; WHO: World Health Organization; PVR: pulmonary vascular resistance; CTEPH: chronic thromboembolic pulmonary hypertension; CTD: connective tissue disease; CPET: cardiopulmonary exercise testing; BNP: brain natriuretic peptide; SSc: systemic sclerosis; APAH: associated PAH.
functional class II) emerged from the EARLY (Endothelin Antagonist Trial in Mildly Symptomatic PAH patients) trial that included a subgroup of patients treated with sildenafil [19]. As patients in this randomised, double-blind, placebo-controlled trial were stratified according to sildenafil use at baseline, concomitant treatment with bosentan could be assessed prospectively. Results showed that, compared with placebo, treatment with bosentan produced significant haemodynamic improvements (reductions in PVR) and prevented clinical deterioration, including in the subgroup of sildenafil-treated patients. Haemodynamic improvement was also observed in COMPASS-1 (Haemodynamic effects of a single dose of sildenafil in symptomatic patients on bosentan treatment for pulmonary arterial hypertension), a prospective, open-label, noncomparative, pharmacodynamic study, in which 45 patients with PAH received single-dose sildenafil on stable bosentan therapy. Here, acute administration of sildenafil produced significant reductions in both PVR (fig. 1) and total pulmonary resistance [20]. Importantly, this trial demonstrated that the pharmacokinetic interaction between bosentan and sildenafil may be of no clinical relevance and, accordingly, that there is a favourable acute pharmacodynamic effect when these drugs are co-administered.

More recently, data were reported from the PHIRST-1 study (Tadalafil in the Treatment of Pulmonary Arterial Hypertension), a randomised, double-blind, placebo-controlled trial in 405 patients with PAH treated with tadalafil [21]. Among this patient population, ~53% (n=216) of patients received tadalafil or placebo in addition to bosentan. Overall, significant improvements in 6MWD and a significant delay in time to clinical worsening were observed in the 40-mg tadalafil dose group, accompanied by improvements in health-related quality of life (HRQoL). In a subgroup analysis, an improvement in exercise capacity was observed in patients who received tadalafil in addition to background bosentan therapy.

**PDE-5 inhibitors plus prostanoids**

As discussed previously, results from the TRIUMPH I study showed that addition of inhaled treprostinil to ongoing sildenafil (or bosentan) therapy led to significant improvements in exercise capacity in patients with advanced PAH (WHO functional class III/IV) [18]. Recently published data from the large randomised, double-blind, placebo-controlled PACES (Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil) trial confirm these findings. This study of 267 patients showed that addition of sildenafil to stable intravenous epoprostenol resulted in a significant improvement in 6MWD compared with placebo (fig. 2) and, furthermore, was accompanied by positive changes in haemodynamics, time to clinical worsening and HRQoL [22]. Combination treatment was generally well tolerated with the benefits being considered to outweigh the increased rates of headache and dyspepsia seen in the combination treatment arm.

Data from large, adequately powered, randomised controlled trials of combination therapy in PAH are only now being published, with further combination treatment studies still in the pipeline. Nonetheless, they point towards encouraging results and augment earlier findings from a number of small studies and case reports, the vast majority of which support the view that combination therapy is beneficial in patients who fail to respond to an initial course of monotherapy or begin to deteriorate while on monotherapy (table 1) [16, 23–45]. In fact, as data from the large REVEAL Registry (Registry to Evaluate Early and Long Term PAH Disease Management) demonstrate, combination therapy is commonly used in clinical practice despite the relative lack of supporting data.

**WHEN SHOULD COMBINATION THERAPY BE CONSIDERED?**

At present there is no known cure for PAH, thus current therapy aims to improve and/or stabilise haemodynamics, symptoms such as dyspnoea, exercise capacity, HRQoL, morbidity (including hospitalisation) and survival [12]. Naturally, these goals will depend on the stage of disease at diagnosis, with prevention of disease progression being the goal in early-stage disease versus clinical improvement in advanced stages. Other factors to take into account include the patient’s physical and mental state, underlying disease and comorbidities, as well as the patient’s priorities and wishes.

As it is important to set treatment goals that are known to be associated with improved outcome, follow-up parameters should not only be repeatable, noninvasive and assessable, but also of prognostic importance. Useful parameters include: 6MWD; cardiopulmonary exercise testing (peak oxygen uptake ($V_{O2}$ max)); haemodynamics (cardiac index and right atrial pressure); and possibly biomarkers, such as brain natriuretic peptide (BNP) and N-terminal pro-BNP. Pulmonary arterial pressure is not considered a suitable follow-up parameter because it correlates poorly with disease severity and is, therefore, of limited prognostic value [12].

A study using a goal-orientated approach to therapy, whereby patients in whom pre-defined treatment goals were met
continued with bosentan while patients who did not meet the treatment goals were successively given sildenafil and then inhaled iloprost, has been shown to provide acceptable long-term results in patients with advanced PAH [7]. In this study, in which treatment goals were a 6MWD of >380 m, a peak \( V'\text{O}_2 \) of >10.4 mL min\(^{-1}\) kg\(^{-1}\) and a peak systolic blood pressure of >120 mmHg during exercise, survival (primary end-point) was significantly better over 3 yrs compared with both historical controls and expected survival estimates (fig. 3), with combination treatment also reducing the need for i.v. prostanoids or lung transplantation. A suggested treatment algorithm based on the results of this study is illustrated in figure 4. In addition to the treatment goals suggested in the algorithm, haemodynamic goals such as a cardiac index >2.4 L min\(^{-1}\) m\(^{-2}\) and a right atrial pressure <10 mmHg assessed by follow-up right heart catheterisation are considered appropriate in other treatment centres; in younger patients a treatment goal for 6MWD of >500 m may also be considered. The algorithm posits that combination therapy should be initiated when no improvement is apparent after 3–6 months of initial treatment, when pre-defined treatment goals have not been met after 3–6 months, or when the patient worsens. Currently, combination therapy appears best suited to patients with suboptimal response to therapy, such as those in WHO functional class III/IV who fail to improve on initial therapy and those in WHO functional class II who fail to stabilise.

An emerging and fascinating concept relates to the use of first-line combination therapy with two drugs in PAH patients as compared to initial monotherapy. This hypothesis was tested in the BREATHE-2 trial, but the small sample size of the study did not allow a definitive conclusion [15]. The appropriate design to assess the efficacy of this strategy appears to be a three-arm study, comparing combination therapy with two arms of monotherapy using the single compounds.

**CONCLUSIONS**

The chronic and rapidly progressive nature of PAH provides a strong rationale for use of combination therapy; indeed, combination therapy is now recommended in new treatment guidelines. Experience to date with combination therapy is encouraging, with multiple combinations proving effective and, importantly, well tolerated. The appropriate timing of combination therapy and whether it should be simultaneously or sequential requires further evaluation. A goal-oriented approach to combination therapy seems to be appropriate given the current available data on efficacy and safety. Patients with PAH should, therefore, be reassessed every 3–6 months and the addition of a new therapy considered when treatment goals have not been met. Controlled clinical trials are underway that will provide important answers to the long-term safety and efficacy of combination therapy in PAH.

**STATEMENT OF INTEREST**

N. Galíé has participated in advisory board activities for Actelion, Pfizer, United Therapeutics, Eli Lilly, Bayer Schering, Encysive and GlaxoSmithKline. He has been a paid lecturer for Actelion, Pfizer, Bayer Schering, and GlaxoSmithKline. His Institute has received grant support from Actelion, Pfizer, United Therapeutics, Eli Lilly, Bayer Schering, Encysive, and GlaxoSmithKline. G. Simonneau has received consulting and lecture fees and research support from Actelion Pharmaceuticals, Bayer Schering, GlaxoSmithKline, Eli Lilly and United Therapeutics.

**ACKNOWLEDGEMENTS**

We received editorial assistance from Elements Communications Ltd (Westerham, UK), supported by Actelion Pharmaceuticals Ltd (Allschwil, Switzerland).

**REFERENCES**

1. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991; 115: 343–349.
2. Farber HW, Loscalzo J. Pulmonary arterial hypertension. *N Engl J Med* 2004; 351: 1655–1665.
3. Simonneau G, Galíé N, Rubin LJ, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43: Suppl. S13–S24.
4. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43: Suppl. 12, S13–S14.
5. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. *Circulation* 2004; 109: 159–165.
6. Galíé N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. *Eur Heart J* 2009; 30: 394–403.
7. Hooper MM, Markevych I, Spikerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. *Eur Respir J* 2005; 26: 858–863.
8. Chin KM, Rubin Lj. Pulmonary arterial hypertension. *J Am Coll Cardiol* 2008; 51: 1527–1538.
9. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update For The Diagnosis And Management Of Chronic Heart Failure In The Adult: a report of the American College of Cardiology/American Heart Association Task Force on...
Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure); developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154–e235.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines For the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, Department of Health and Human Services, 2008; 1–139. Available from: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

Blansfield JA, Caragaciu I, Alexander HR 3rd, et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008; 14: 270–280.

Galié N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243–2278.

Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 355–625.

Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917–1928.

Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATH-E-2. Eur Respir J 2004; 24: 353–359.

McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257–1263.

Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48: 1433–1437.

McLaughlin V, Rubin L, Benza R. TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2008; 177: A965.

Galié N, Rubin LJ, Hoepfer M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.

Gruenig E, Michelakis E, Vachieri J-L, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Cardiovasc Pharmacol 2009; in press.

Galié N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.

Simonneau G, Rubin LJ, Galié N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521–530.

Petkov V, Ziesche R, Mosgoller W, et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001; 56: 734–736.

Durongpisitkul K, Jakrapanichkul D, Laoaphrasitporn D, et al. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J Med Assoc Thai 2005; 88: Suppl. 8, S60–S65.

Hoepfer MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving non-parentreral prostanooids. Eur Respir J 2003; 22: 330–334.

Seyfarth HJ, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005; 128: 709–713.

Ivy DD, Doran A, Clausen L, et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93: 943–946.

Akagi S, Matsubara H, Miyaji K, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72: 1142–1146.

Gomberg-Maitland M, McLaughlin V, Gulati M, et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005; 96: 1334–1336.

Benza RL, Rayburn BK, Tailaj A, et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008; 134: 139–145.

Katoaka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461–465.

Stieberlehner L, Petrov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous i.v. epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123: 1293–1295.

Wilkins H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218–1222.

Ghofrani HA, Wiedemann K, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515–522.

Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158–164.

Ruiz MJ, Escobedo P, Delgado JF, et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J Heart Lung Transplant 2006; 25: 1353–1357.

García Hernández FJ, Ocaña Medina C, Mateos Romero L, et al. Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension: report of 4 cases. Med Clin (Barc) 2004; 122: 64–66.

Hoepfer MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007–1010.

Minai OA, Arroliga AC. Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. South Med J 2006; 99: 880–883.

Lunze K, Gilbert N, Mebus S, et al. Efficacy of anticancer therapy. Agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008; 14: 270–280.

Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469–475.

Porhownik NR, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J 2008; 15: 427–430.

Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589–595.

Hoepfer MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691–694.

Miwa K, Matsubara T, Uno Y, et al. Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome. Int Heart J 2007; 48 417–422.